摘要
非酒精性脂肪性肝病(NAFLD)的诊断是一个排除性诊断,其名也未能反映疾病的本质和发生机制。最近,国际上相继提出MAFLD和MASLD的新命名,汉语都翻译为代谢相关脂肪性肝病。新命名反映了本病的始动因素及其发生和发展过程,并和临床结局显著相关联,并提示MASLD(MAFLD)是一个有可能通过对代谢障碍进行干预而改善临床结局的肝脏疾病(全身疾病在肝脏的表现)。
The diagnosis of nonalcoholic fatty liver disease(NAFLD)is an exclusionary diagnosis,and the name does not reflect the disease’s nature or mechanism.Internationally,MAFLD(metabolic dysfunction-associated fatty liver disease)and MASLD(metabolic dysfunction-associated steatotic liver disease)have recently been proposed,which are translated as metabolic dysfunction-associated fatty liver disease in Chinese.The new name reflects the initiating factors of the disease,its occurrence and development process,and the clinical significance of associated outcomes.Through interventions against metabolic disorders,liver disease(hepatic manifestations of systemic disease)reflecting MASLD(MAFLD)has the potential to improve clinical outcomes.
作者
薛峰
魏来
Xue Feng;Wei Lai(Hepatopancreatobiliary Center,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing 102218,China)
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2023年第8期785-788,共4页
Chinese Journal of Hepatology
基金
国家重点研发计划(2022YFA1303804)。
关键词
脂肪性肝病
临床结局
新药
Fatty liver disease
Clinical outcome
New drug
